 AUSTIN, Texas, Jan. 19, 2022 PRNewswire -- Natera, Inc. NASDAQ: NTRA, a leader in personalized genetic testing and diagnostics, today announced the company, along with its collaborators, will present new data on Nateras personalized, tumor-informed molecular residual disease MRD test, Signatera, at the American Society of Clinical Oncologys 2022 Gastrointestinal Cancers Symposium ASCO GI, taking place January 20 22, 2022. Natera has two oral presentations and four collaborative poster presentations highlighting clinical findings on the performance of Signatera across colorectal CRC, pancreatic and anal cancers. 